These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 34040367)

  • 1. The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients.
    Song Q; Zhao YY; Zeng YQ; Liu C; Cheng W; Deng MH; Li X; Ma LB; Chen Y; Cai S; Chen P
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1401-1412. PubMed ID: 34040367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
    Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
    BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk assessment of intensive care unit admission for postoperative patients with stable chronic obstructive pulmonary disease].
    Fan J; Zhao L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Oct; 33(10):1209-1214. PubMed ID: 34955130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population.
    Liu D; Song Q; Zeng Y; Yi R; Liu Y; Li X; Chen Y; Cai S; Chen P
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1741-1751. PubMed ID: 37599897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry.
    Kobayashi S; Hanagama M; Ishida M; Sato H; Ono M; Yamanda S; Yamada M; Aizawa H; Yanai M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3947-3955. PubMed ID: 30584294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review.
    Czira A; Purushotham S; Iheanacho I; Rothnie KJ; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():719-731. PubMed ID: 37151760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients.
    Kawamatawong T; Onnipa J; Suwatanapongched T
    Int J Chron Obstruct Pulmon Dis; 2018; 13():761-769. PubMed ID: 29535516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan.
    Oishi K; Hirano T; Hamada K; Uehara S; Suetake R; Yamaji Y; Ito K; Asami-Noyama M; Edakuni N; Matsunaga K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3901-3907. PubMed ID: 30584291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship Between Clinical Phenotypes and Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stages/Groups in Patients With Chronic Obstructive Pulmonary Disease.
    Pandey AK; Verma AK; Singh A; Kant S; Dixit RK; Chaudhary SC; Bajpai J; Prakash V; Verma UP
    Cureus; 2022 Dec; 14(12):e32116. PubMed ID: 36601200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of Clinical COPD Questionnaire in Patients with COPD: A Cross-Sectional Observational Study.
    Zhou Z; Zhou A; Peng Y; Duan J; Zeng Y; Zhao Y; Cheng W; Chen P
    Respiration; 2020; 99(7):606-616. PubMed ID: 32659763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
    Pelaia C; Procopio G; Deodato MR; Florio O; Maglio A; Sciacqua A; Vatrella A; Pelaia G
    Respiration; 2021; 100(2):127-134. PubMed ID: 33302284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
    Ivanov Y; Nikolaev I; Nemeth I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
    Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and risk factors for inconsistency between the risk of exacerbations and the severity of airflow limitation in COPD based on GOLD 2017: A retrospective, cross-sectional study.
    Huang WC; Wu MF; Chen HC; Hsu JY;
    PLoS One; 2018; 13(3):e0193880. PubMed ID: 29529075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.